ARQT

Arcutis Biotherapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1787306Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$376.0M

Net Income FY2025

$(16.0M)

EPS (Basic, as reported)

$-0.13

Net Margin FY2025

-4.3%

ROE FY2025

-8.5%

Total Equity

$189.0M

Shares Out

126M

Business description

Arcutis Biotherapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 376

Fiscal yearFY2018FY2019⚑FY2020FY2021FY2022FY2023⚑FY2024FY2025

Revenue——00460197376

Cost of revenue———0(1)(5)(19)(37)

Research & development(18)(37)(115)(146)(182)(111)(76)(77)

Selling, general & administrative———(61)(122)(185)(229)(275)

General & administrative(2)(7)(21)(61)(122)———

Total operating expenses(20)(43)(137)(207)(305)(301)(325)(388)

Operating income(20)(43)(137)(207)(302)(241)(128)(12)

Interest expense——00(16)(30)(27)(12)

Other income (expense), net0110(10)1200

Income tax expense00000(3)(1)(1)

Net income(19)(42)(136)(206)(311)(262)(140)(16)

EPS — basic—($22.78)($3.80)($4.18)($5.66)($3.78)($1.16)($0.13)

EPS — diluted—($22.78)($3.80)($4.18)($5.66)($3.78)($1.16)($0.13)

Shares outstanding — basic (M)—236495569121127

Shares outstanding — diluted (M)—236495569121127

⚑ Weighted-average shares changed ×18.00 between FY2019 and FY2020 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.75 between FY2023 and FY2024 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.